Associated Papers
Comprehensive genomic landscape of metastatic hormone-sensitive prostate cancer in the Chinese population.
Yang B et al.
World Journal of Surgical Oncology, 2025
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.
Wang LY et al.
Innovation (cambridge (mass.)), 2025
Genomic landscape and comparative analysis of tissue and liquid-based NGS in Taiwanese anaplastic thyroid carcinoma.
Yeh CN et al.
Npj Precision Oncology, 2025
Genetic variants, haplotype determination, and function of novel alleles of CYP2B6 in a Han Chinese population.
Zhang LQ et al.
Heliyon, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
Zhou Y et al.
The Pharmacogenomics Journal, 2022
Methadone pharmacogenetics in vitro and in vivo: Metabolism by CYP2B6 polymorphic variants and genetic variability in paediatric disposition.
Wang PF et al.
British Journal of Clinical Pharmacology, 2022
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
Lanillos J et al.
Npj Genomic Medicine, 2022
Rare Variation in Drug Metabolism and Long QT Genes and the Genetic Susceptibility to Acquired Long QT Syndrome.
Gray B et al.
Circulation. Genomic and Precision Medicine, 2022
Sequencing of a Chinese tetralogy of Fallot cohort reveals clustering mutations in myogenic heart progenitors.
Tang CSM et al.
Jci Insight, 2022
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
The Pharmacogenetics of Efavirenz Metabolism in Children: The Potential Genetic and Medical Contributions to Child Development in the Context of Long-Term ARV Treatment.
Tan M et al.
New Directions for Child and Adolescent Development, 2020
The GenomeAsia 100K Project enables genetic discoveries across Asia.
Unknown Author
Nature, 2019
Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma.
Su D et al.
Nature Communications, 2019
Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry.
Wang PF et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2019
Nicotine oxidation by genetic variants of CYP2B6 and in human brain microsomes.
Bloom AJ et al.
Pharmacology Research & Perspectives, 2019
A Novel Silent Mutation in the L1CAM Gene Causing Fetal Hydrocephalus Detected by Whole-Exome Sequencing.
Sun Y et al.
Frontiers in Genetics, 2019
Stereoselective Ketamine Metabolism by Genetic Variants of Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase.
Wang PF et al.
Anesthesiology, 2018
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Association of CYP2B6 gene polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese population.
Wang Y et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases, 2017
Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.
Calcagno A et al.
Clinical Pharmacokinetics, 2017
The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children.
Bienczak A et al.
British Journal of Clinical Pharmacology, 2016
The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand.
Bushyakanist A et al.
Pharmacogenomics and Personalized Medicine, 2015
A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study.
Damronglerd P et al.
Pharmacogenomics and Personalized Medicine, 2015
Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.
Nichols AC et al.
Bmc Pharmacology & Toxicology, 2014
Pharmacogenetics of antiretroviral therapy.
Barreiro P et al.
Expert Opinion on Drug Metabolism & Toxicology, 2014
Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism.
Sukasem C et al.
Infection, 2014
CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy.
Manosuthi W et al.
International Journal of Antimicrobial Agents, 2014
CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.
Manosuthi W et al.
Antimicrobial Agents and Chemotherapy, 2014
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Manosuthi W et al.
Antimicrobial Agents and Chemotherapy, 2013
High plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections.
Sukasem C et al.
Drug Metabolism and Pharmacokinetics, 2013
Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.
Sukasem C et al.
British Journal of Clinical Pharmacology, 2012
Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients.
Gounden V et al.
Aids Research and Therapy, 2010
Efavirenz in the therapy of HIV infection.
Rakhmanina NY et al.
Expert Opinion on Drug Metabolism & Toxicology, 2010
Allele and genotype frequencies of cytochrome P450 2B6 gene in a Mongolian population.
Davaalkham J et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
Pharmacogenetics of antiretroviral agents.
Owen A et al.
Current Opinion in Hiv and Aids, 2008
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
Wyen C et al.
The Journal of Antimicrobial Chemotherapy, 2008
Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.
Gatanaga H et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 2007
Japanese single nucleotide polymorphism database for 267 possible drug-related genes.
Iida A et al.
Cancer Science, 2006
The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview.
Ferraro TN et al.
Epilepsy & Behavior : E&b, 2005
[SNP collection, pharmacogenomics, and the future of drug therapy].
Iida A et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy, 2002